Clinical trials: Osteoporosis Postmenopausal
Osteoporosis
Effects of Parathyroid Hormone in Men With Osteoporosis
Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH) stimulates the formation of new bone. The purpose of this study is to compare the bone-building effects of PTH alone, alendronate alone, and…
- Trial name
- NCT00000427
- Testing
- Parathyroid hormone, Alendronate
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Post-Menopausal
Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, are able to produce reliable changes in the bone marker in a severe osteoporotic population
- Trial name
- NCT00532545
- Testing
- Teriparatide
- Where
- 7 sites in Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Osteoporosis
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
The aim of this study is to determine the effect of aromatase inhibitors therapy on bone mineral density and compare it to the effects of tamoxifen and no hormonal therapy.
- Trial name
- NCT00767585
- Where
- Slovenia
- Volunteers
- 560 people
- Sponsor
- AstraZeneca
Osteoporosis
A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)
The study will evaluate the both the efficacy of odanacatib on Bone Mineral Density (BMD) and the safety of odanacatib for postmenopausal osteoporosis in patients previously treated with alendronate.
- Trial name
- NCT00885170
- Testing
- Odanacatib, Vitamin D3, Calcium
- Volunteers
- 246 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis
Increased bone formation in the absence of accelerated resorption is resulting in a marked anabolic response to teriparatide (TPTD) during the early phase after treatment initiation.
- Trial name
- Confors (NCT01535027)
- Testing
- teriparatide, teriparatide and raloxifene, teriparatide and alendronate
- Where
- Austria
- Volunteers
- 125 people
- Sponsor
- Medical University of Vienna
Osteoporosis, Postmenopausal
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
This randomized open label clinical trial will evaluate the effect of continued denosumab alone over 18 months versus denosumab with added abaloparatide for 18 months.
- Trial name
- NCT04467983
- Testing
- Denosumab Injection, Abaloparatide
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Osteoporosis in Postmenopausal Women
Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)
Primary objective: To compare the bone mineral density (BMD) change under the treatment of denosumab with eldecalcitol or native vitamin D in postmenopausal women with osteoporosis on bone mineral density.
- Trial name
- ESCORT (NCT05884372)
- Testing
- Eldecalcitol, Native Vitamin D, Denosumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xi'an Honghui Hospital
Postmenopausal Osteoporosis
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were…
- Trial name
- STRUCTURE (NCT01796301)
- Testing
- Romozosumab, Teriparatide
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 436 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Study of Transitioning From Alendronate to Denosumab
The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab.
- Trial name
- NCT00377819
- Testing
- alendronate, Denosumab (AMG 162)
- Volunteers
- 504 people
- Sponsor
- Amgen
Osteoarthritis
Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin
Relacatib is being developed for the treatment of osteoporosis, osteoarthritis and possibly other bone disorders. Recent results suggest that relacatib interacts with the way our bodies metabolise drugs and so some drugs which…
- Trial name
- NCT00411190
- Testing
- Relacatib, Acetaminophen, Ibuprofen
- Where
- 2 sites in Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteopenia, Osteoporosis
Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis
The aim of the 2 month randomized controlled trial is to investigate the feasibility of a novel progressive muscle resistance exercise in individuals with low bone mass.
- Conditions
- Osteopenia, Osteoporosis, Postmenopausal Osteoporosis, Sarcopenia
- Trial name
- NCT05060380
- Testing
- Exercise training
- Sponsor
- University of Alabama at Birmingham
Postmenopausal Osteoporosis
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.
- Trial name
- NCT01750086
- Testing
- Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Postmenopausal
Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of MW031 and Prolia® in healthy adults.
- Trial name
- MW031 (NCT04798313)
- Testing
- MW031, Prolia®
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Osteoporosis
Role of Oxytocin in Post-menopausal Osteoporosis: Evaluation on the Population of the OPUS Cohort
Oxytocin is a neurohypophysial hormone involved in several central and peripheral functions including parturition, milk let-down reflex and social behaviour.
- Trial name
- NCT01192893
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Osteoporosis
Orthorexia Nervosa in Postmenopausal Osteoporosis
A total of 64 female patients diagnosed with osteoporosis based on dual-energy X-ray absorptiometry (DXA) measurements performed within the last six months, and 64 age-matched healthy controls without osteoporosis, will be…
- Trial name
- NCT06947213
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people
- Sponsor
- Beylikduzu State Hospital
Osteoporosis, Postmenopausal
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
The purpose of this study is to determine whether the increase in spine bone mineral density that has been generally observed in previous clinical studies involving the study drug can be maintained or even increased if followed…
- Trial name
- NCT00035256
- Testing
- teriparatide, raloxifene HCl
- Where
- 5 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Eli Lilly and Company
Post Menopausal Osteoporosis
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis.
- Trial name
- NCT01290094
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 2 sites in Bosnia and Herzegovina
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Osteopenia, Osteoporosis
Intervention Study of Drugs in Patients Osteopenia and Osteoporosis
This is a 12 months, randomized, multicenter, open-label, parallel-group study in postmenopausal women and male aged 50 years or old with osteoporosis or osteopenia in China to evaluate the efficacy and safety of different…
- Trial name
- NCT04719572
- Testing
- Basic treatment group, Basic treatment+ anti-osteoporosis drug group, Basic treatment + non-drug treatment group
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Chinese PLA General Hospital
Osteopenia
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of…
- Trial name
- NCT00310531
- Testing
- Menostar (Estradiol, BAY86-5435), Raloxifene
- Volunteers
- 500 people
- Sponsor
- Bayer
Osteoporosis, Postmenopausal
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
The primary objective of this study is to demonstrate a reduction in the proportion of new vertebral fractures in postmenopausal women with osteoporosis following 3-years of treatment with 20 and 40 mcg/day of teriparatide plus…
- Trial name
- NCT00670501
- Testing
- teriparatide, Calcium Supplement, Vitamin D Supplement
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 1,637 people
- Sponsor
- Eli Lilly and Company